From 5 October 2025 - 10:00 AM (CEST)
To 7 October 2025
Add to Calendar
Add to Calendar
2025-10-05T08:00:00
2025-10-07T17:00:00
UEG Week 2025
<h2>Join Diasorin at the UEG Week 2025</h2><h2>October 5 - 7 - Hall 4.2. Booth #4.02!</h2><h6><br>Come visit us at UEG Week 2025, where we are excited to share with you our diagnostic solutions for GI Disorders: <br> </h6><ul><li>Inflammatory Bowel Disease (IBD) vs Irritable Bowel Syndrome (IBS)</li><li>Monitoring IBD</li><li>Exocrine Pancreatic Insufficiency (EPI)</li><li>Bacterial & Viral Infections</li><li>Hepatitis Diagnostic Solutions</li></ul><p>At Diasorin, we support clinicians in delivering better patient outcomes through accurate, clinically relevant diagnostic tools for gastrointestinal diseases. Our portfolio includes a wide range of assays that help you address the most common and complex GI challenges - from distinguishing overlapping symptoms to identifying infectious causes and guiding treatment decisions. </p><h6>Our Assay Menu </h6><p><strong>Calprotectin · Elastase-1 · </strong><em><strong> C. difficile</strong></em><strong> GDH · </strong><em><strong>C. difficile </strong></em><strong>Toxins A&B · </strong><em><strong>H. pylori Ag</strong></em><strong> · Campylobacter Ag · Adenovirus · Rotavirus · tTG IgA · Hepatitis A, Hepatitis B, Hepatitis C, Hepatitis D, and Hepatitis E </strong></p><p>Whether you are working in primary or secondary care, conducting research, or supporting patients as a nurse, we’d love to welcome you at our booth to explore how our solutions can give you the clarity and confidence to act quickly and effectively. </p><h6>Survey: Understanding Diagnostic Practices in Stool</h6><p>We invite all congress attendees to participate in our short survey. Your insights will help us better understand current practices, challenges, and needs in gastrointestinal diagnostics. <br><a href="https://forms.office.com/r/R16BZWMnAX" target="_blank" rel="noopener noreferrer">Take the survey</a></p><h6>Highlighted Scientific Publications</h6><p><strong>Calprotectin </strong></p><ul><li>Campbell, J. <em>et al.</em> 2021. Clinical Performance of a Novel LIAISON Fecal Calprotectin Assay for Differentiation of Inflammatory Bowel Disease From Irritable Bowel Syndrome. <a href="https://doi.org/10.1097/mcg.0000000000001359">DOI:10.1097/MCG.0000000000001359</a></li><li>Fiorino <em>et al.</em> 2022. LIAISON® Calprotectin for the prediction of relapse in quiescent ulcerative colitis: The EuReCa study. <a href="https://doi.org/10.1002/ueg2.12268">DOI: 10.1002/ueg2.12268</a></li><li>Osredkar J. <em>et al.</em> 2021. The comparison of the three assays for determination of fecal calprotectin in inflammatory bowel disease. <a href="https://doi.org/10.11613/BM.2021.020707">DOI: https://doi.org/10.11613/BM.2021.020707</a></li><li>Pelkmans, L. <em>et al.</em> 2019. Analytical Performance and Clinicopathologic Correlation of Four Fecal Calprotectin Methods. <a href="https://academic.oup.com/ajcp/article/152/3/392/5509899">DOI: 10.1093/AJCP/AQZ051</a></li><li>Wyness, S. <em>et al.</em> 2021. Clinical and Analytical Verification of an Automated Fecal Calprotectin Immunoassay with Extraction Device. <a href="https://academic.oup.com/jalm/article/6/4/931/6134832">DOI: 10.1093/jalm/jfaa236</a></li></ul><p><em><strong>Helicobacter pylori</strong></em></p><ul><li>Resina, E. <em>et al.</em> 2022. Evaluation of a New Monoclonal Chemiluminescent Immunoassay Stool Antigen Test for the Diagnosis of <em>Helicobacter pylori</em> Infection: A Spanish Multicentre Study. Journal of Clinical Medicine, 11, 5077. <a href="https://doi.org/10.3390/jcm11175077">DOI: 10.3390/jcm11175077</a></li></ul><p><strong>Elastase</strong></p><ul><li>Handley, S. <em>et al.</em> 2023. Verification of the Bühlmann fPELA turbo Faecal Elastase Assay on the Binding Site Optilite Benchtop Analyser. Annals of Clinical Biochemistry, 60(1), 68–71. <a href="https://doi.org/10.1177/00045632221138025">DOI: 10.1177/00045632221138025</a></li><li>Huta Y. <em>et al.</em> 2022. A Novel Fecal Elastase Assay for the Detection of Pancreatic Exocrine Insufficiency. Clinical Laboratory, 68, 1476–1480. <a href="DOI: 10.7754/Clin.Lab.2021.211206">DOI: 10.7754/Clin.Lab.2021.211206</a></li><li>Wyness, S. <em>et al.</em> 2022. Clinical and Analytical Characterization of the DiaSorin and ScheBo Fecal Pancreatic Elastase 1 Assays. Pancreas, 51(3), 243–249. <a href="https://doi.org/10.1097/mpa.0000000000002006">DOI: 10.1097/MPA.0000000000002006</a></li></ul><p><em><strong>Clostridium difficile</strong></em></p><ul><li>Blanco-Hernández, A., <em>et al. </em>2025. Testing suitability of Cary-Blair medium for detection of <em>Clostridioides difficile</em> in stool samples by chemiluminiscence immunoassay. Diagnostic Microbiology and Infectious Disease, 113, 116959. <a href="https://doi.org/10.1016/j.diagmicrobio.2025.116959">https://doi.org/10.1016/j.diagmicrobio.2025.116959D</a></li></ul><p> </p>
Berlin, Germany
Diasorin
diasorin@nomail.com
Europe/Berlin
public
